Eli Lilly’s Orforglipron Clears First Late-Stage Trial, Boosts Weight Loss Hopes April 17, 2025 Indianapolis, IN – Eli Lilly’s experimental oral weight reduction tablet, orforglipron, met its objectives within the first of seven late-stage trials, serving to Sort 2 diabetes sufferers lose 7.9% of physique weight (16 kilos) and decrease blood sugar over 40 weeks, … Read more
Atlanta, GA — The Centers for Disease Control and Prevention (CDC) has directed all staff to resume on-site work at its Atlanta headquarters no later than Monday, September 15, 2025, five weeks after a deadly shooting rocked the agency’s Roybal Campus. The announcement, made by new Chief Operating Officer Lynda Chapman in an internal email … Read more
The Amgen emblem is displayed exterior Amgen headquarters in Thousand Oaks, California, on Might 17, 2023. Amgen on Wednesday stated it has began two vital late-stage trials for its experimental weight reduction injection MariTide, one other step in its bid to enter the booming weight problems drug market. “We’re delighted to share that these trials … Read more
As of my last knowledge update, Walgreens Boots Alliance (WBA) has not yet released its Q2 2025 earnings report. However, based on historical trends and recent developments, here’s what to expect: Expected Walgreens (WBA) Q2 2025 Earnings Overview Earnings Release Date: Likely late March or early April 2025 (exact date TBA). Previous Quarter (Q1 2025) Recap: Revenue: ~$36-37B (slight YoY decline). … Read more
Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more
Biotechnology giant Amgen Inc. has announced a major investment exceeding $600 million to construct a state-of-the-art research and development (R&D) center at its global headquarters in Thousand Oaks, California. This move underscores the company’s commitment to advancing scientific innovation amid a shifting U.S. pharmaceutical landscape, where domestic investments are surging in response to potential trade … Read more
Eli Lilly’s $5 Billion Bet on Virginia: A Game-Changer for U.S. Drug Manufacturing In a bold move to fortify America’s pharmaceutical backbone amid looming trade tensions and surging demand for cutting-edge therapies, Eli Lilly and Company announced plans on September 16, 2025, to invest $5 billion in a state-of-the-art manufacturing facility in Goochland County, Virginia—just … Read more